These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25039861)

  • 1. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B.
    Hsiang JC; Wong GL; Chan HL; Chan AW; Chim AM; Wong VW
    Aliment Pharmacol Ther; 2014 Sep; 40(6):716-26. PubMed ID: 25039861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study.
    Chen YC; Jeng WJ; Hsu CW; Lin CY
    BMC Gastroenterol; 2020 May; 20(1):146. PubMed ID: 32397963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis.
    Shin H; Choi WM; Kim SU; Ko Y; Park Y; Park J; Hur MH; Park MK; Lee YB; Kim YJ; Yoon JH; Lee JH; Zoulim F
    JHEP Rep; 2024 Jul; 6(7):101089. PubMed ID: 38974365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.
    Fung J; Wong DK; Seto WK; Kopaniszen M; Lai CL; Yuen MF
    Am J Gastroenterol; 2014 Nov; 109(11):1764-70. PubMed ID: 25244963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.
    Yang HI; Hung HL; Lee MH; Liu J; Jen CL; Su J; Wang LY; Lu SN; You SL; Iloeje UH; Chen CJ;
    Clin Gastroenterol Hepatol; 2012 May; 10(5):527-34.e1-2. PubMed ID: 22178461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.
    Mak LY; Seto WK; Hui RW; Fung J; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Jul; 26(7):818-827. PubMed ID: 30895682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Gu Y; Zhang Y; Zhang Z; Wang J; Zhang Q; Zhang S; Liu Y; Liu J; Xia J; Yan X; Li J; Liu X; Huang R; Wu C
    Ann Hepatol; 2024; 29(1):101151. PubMed ID: 37704066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
    Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
    J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
    Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B.
    Danta M; Bradshaw D
    Aliment Pharmacol Ther; 2014 Oct; 40(8):982. PubMed ID: 25229811
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Yang SS; Yeh HZ; Chang CS; Peng YC
    PLoS One; 2019; 14(8):e0221958. PubMed ID: 31469875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct seromarkers predict different milestones of chronic hepatitis B progression.
    Liu J; Yang HI; Lee MH; Batrla-Utermann R; Jen CL; Lu SN; Wang LY; You SL; Hsiao CK; Chen CJ;
    Hepatology; 2014 Jul; 60(1):77-86. PubMed ID: 24700432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance.
    Kim S; Yoo S; Lee JI; Kim S; Chang HY; Kim D; Jeong SH; Lee KS; Lee HW
    Dig Dis Sci; 2022 Jan; 67(1):321-328. PubMed ID: 33517556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
    Zhu F; Zhang Q; Zhang Q; Zhang D
    Microb Pathog; 2020 Feb; 139():103912. PubMed ID: 31816402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.